1	Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD
2	protein vaccine against COVID-19 in adults: pooled analysis of two randomized,
3	double-blind, placebo-controlled, phase 1 and 2 trials
4	
5	Shilong Yang*, Yan Li*, Lianpan Dai*, Jianfeng Wang*, Peng He*, Changgui Li, Xin
6	Fang, Chenfei Wang, Xiang Zhao, Enqi Huang, Changwei Wu, Zaixin Zhong, Fengze
7	Wang, Xiaomin Duan, Siyu Tian, Lili Wu, Yan Liu, Yi Luo, Zhihai Chen, Fangjun Li,
8	Junhua Li, Xian Yu, Hong Ren, Lihong Liu, Shufang Meng [†] , Jinghua Yan [†] , Zhongyu
9	Hu [†] , Lidong Gao [†] , George F. Gao [†]
10	
11	Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., HeFei, China (S Yang, E Huang, C
12	Wu, Z Zhong);
13	CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of
14	Microbiology, Chinese Academy of Sciences, Beijing, China (Y Li, L Dai, G F Gao);
15	CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of
16	Microbiology, Chinese Academy of Sciences, Beijing, China (F Wang, X Duan, S Tian,
17	L Wu, J Yan);
18	National Institute for Food and Drug Control, Beijing, China (J Wang, P He, X Zhao, X
19	Fang, C Wang, C Li, S Meng, Z Hu);
20	Hunan Provincial Center for Diseases Control and Prevention, Changsha, China (F Li,
21	J Li, L Gao);
22	The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China (X

23	Yu.	Н	Ren)):
20	· •··,		,	,

- 24 Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China (L Liu);
- 25 Center of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing,

26 China (Z Chen);

- 27 Beijing Keytech Statistical Technology Co. Ltd., Beijing, China (Y Luo);
- 28 Chongqing Medleader Bio-Pharm Co. Ltd., Chongqing, China (Y Liu)

29

30 * Contributed equally

31 [†] Correspondence to:

- 32 George F. Gao, CAS Key Laboratory of Pathogenic Microbiology and Immunology,
- 33 Institute of Microbiology, Chinese Academy of Sciences, Beijing 10010, China.

34 gaof@im.ac.cn

- or Lidong Gao, Hunan Provincial Center for Diseases Control and Prevention,
- 36 Changsha 410005, China. gldlj@hotmail.com
- or Zhongyu Hu, National Institute for Food and Drug Control, Beijing 100050, China.
- 38 huzhy@nifdc.org.cn
- 39 or Jinghua Yan, CAS Key Laboratory of Microbial Physiological and Metabolic
- 40 Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 10010,
- 41 China. yanjh@im.ac.cn
- 42 or Shufang Meng, National Institute for Food and Drug Control, Beijing 100050, China.
- 43 mengsf@263.net
- 44

45 **Research in context:**

46

47 Evidence before this study

48 We searched for ClinicalTrials.gov and PubMed up to Dec 11, 2020, with the terms "COVID-19", "SARS-CoV-2" and "vaccine". No language restrictions were applied. We 49 identified 56 vaccine candidates being evaluated in clinical trials, with 12 in phase 3 50 trials. Thirteen phase 1 and/or phase 2 studies have been published, regarding to 4 51 52 inactivated vaccines, 3 adenovirus vectored vaccines, 2 mRNA-based vaccines and 1 53 protein subunit vaccine. Two phase 3 studies have been published. These vaccines 54 with published data are mainly targeting either whole virus or spike protein. One RBDbased vaccine (BNT162b1, developed by BioNTech and Pfizer) was reported using 55 mRNA expressing RBD-trimer, showing the vaccine is tolerant and immunogenic. The 56 57 only published protein subunit vaccine (NVX-CoV2373, developed by Novavax) is based on modified spike protein with Matrix-M1 as adjuvant. To date, a large number 58 of RBD-based protein subunit vaccines are under clinical and pre-clinical evaluations 59 60 (http://www.who.int), but no clinical studies have been published.

61

62 Added value of this study

2F2001 is one of the two protein-based COVID-19 vaccine candidates that advanced into phase 3 clinical trials but is the first RBD-based protein subunit vaccine reported for clinical data. Clinical data for protein subunit COVID-19 vaccine using conventional alum adjuvant was first described here. The phase 1 and phase 2 trials evaluated the safety profile, immunogenicity, dose-effect and vaccination schedule for

68	ZF2001. This candidate is well-tolerated, without vaccine-related serious adverse
69	events. Three immunizations at day 0, 30 and 60 achieved 93-100% seroconversion
70	of neutralizing antibodies, with the GMTs exceeding the magnitude of the convalescent
71	samples. Also, this vaccine elicited moderate cellular immune responses, detected as
72	the balanced production of $T_H 1/T_H 2$ cell-associated cytokines.
73	
74	Implications of all the available evidence
75	Our findings indicated that RBD-based protein subunit vaccine is safe and
76	immunogenic. Further clinical trials should be performed to investigate its protective
77	efficacy
78	
79	Summary:
80	
81	Background
82	A safe and effective coronavirus disease 2019 (COVID-19) vaccine is urgently
83	needed to control the ongoing pandemic. Although progress has been made recently
84	with several candidates reporting positive efficacy results, COVID-19 vaccines
85	developed so far cannot meet the global vaccine demand. We developed a protein
86	subunit vaccine against COVID-19, using dimeric form of receptor-binding domain

(RBD) as the antigen. We aimed to assess the safety and immunogenicity of this
vaccine in humans and determine the appropriate dose and schedule for an efficacy

89 study.

90

91 Methods

92 We did two randomized, double-blind, placebo-controlled, phase 1 and 2 trials for 93 an RBD-based protein subunit vaccine, ZF2001. In phase 1 study, 50 healthy adults 94 aged 18-59 years were enrolled and randomly allocated to three groups to receive three doses of vaccine (25 µg or 50 µg RBD-dimer, with adjuvant) or placebo (adjuvant-95 only) intramuscularly, 30 days apart. In phase 2 study, 900 healthy adults aged 18-59 96 97 years were enrolled and randomly allocated to six groups to receive vaccine (25 µg or 98 50 µg RBD-dimer, with adjuvant) or placebo (adjuvant-only) intramuscularly, with the former 3 groups given two doses and the latter 3 groups given three doses, 30 days 99 apart. For phase 1 trial, the primary outcome was safety, as measured by the 100 101 occurrence of adverse events and serious adverse events. The secondary outcome was immunogenicity as measured by the seroconversion rate and magnitude of 102 antigen-binding antibodies, neutralizing antibodies and T-cell cytokine production. For 103 104 phase 2 trial, the primary outcome included both safety and immunogenicity. These 105 trials are registered with ClinicaTrials.gov, NCT04445194 and NCT04466085.

106

107 Findings

Between June 22 and September 15, 2020, 50 participants were enrolled to the phase 1 study (mean age 32.6 years) and 900 participants were enrolled to phase 2 study (mean age 43.5 years), to receive vaccine or placebo with a two-dose or threedose schedule. For both trials, local and systemic adverse reactions were absent or

112	mild in most participants. There were no serious adverse events related to vaccine in
113	either trial. After three doses, neutralizing antibodies were detected in all participants
114	receiving either 25 μg or 50 μg dose of vaccine in phase 1 study, and in 97% (the 25
115	μg group) and 93% (the 50 μg group) of participants, respectively, in phase 2 study.
116	The SARS-CoV-2-neutralizing geometric mean titres (GMTs) were 94.5 for the 25 μ g
117	group and 117.8 for the 50 μg group in phase 1, and 102.5 for the 25 μg group and
118	69.1 for the 50 μ g group in phase 2, exceeding the level of a panel of COVID-19
119	convalescent samples (GMT, 51). Vaccine induced balanced $T_{\rm H}1$ and $T_{\rm H}2$ responses.
120	The 50 μg group did not show enhanced immunogenicity compared with the 25 μg
121	group.

122

123 Interpretation

The protein subunit vaccine ZF2001 is well-tolerated and immunogenic. The safety and immunogenicity data from phase 1 and 2 trials for ZF2001 support the use of 25 µg vaccine dose with three-dose schedule to an ongoing phase 3 large-scale evaluation for safety and efficacy.

128

129 Funding

130 National Program on Key Research Project of China, National Science and Technology

131 Major Projects of Drug Discovery, Strategic Priority Research Program of the Chinese

132 Academy of Sciences, and Anhui Zhifei Longcom Biopharmaceutical.

133

134 Introduction:

135

The coronavirus disease in 2019 (COVID-19) pandemic caused by severe acute 136 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still growing worldwide.¹ 137 As of Dec 11, 2020, over 69 million people have been diagnosed with COVID-19 in 138 220 countries and regions, with 1.5 million deaths (http://www.who.int). To date, no 139 COVID-19 vaccine has been licensed, although several of them have been approved 140 for emergency use authorization.² 141 142 Since the COVID-19 pandemic, safe and effective vaccines are highly demanded to control the disease and reboot the society and economics. After one-year global efforts, 143 great progresses have been made for COVID-19 vaccine development,³⁻¹⁷ with several 144 145 candidates developed based on mRNA or virus-vector platform announced protective efficacy more than 70-90% in preventing COVID-19 after an interim analysis.¹⁸⁻²⁰ 146 However, these vaccines so far cannot meet the global vaccination demands from 147 148 different subpopulations living in different surroundings. Besides, the efficacy duration and vaccine-related safety concerns are yet to be further determined.²¹ An ideal 149 COVID-19 vaccine should be of high protective efficacy, but safe and deployable for 150 billions of potential vaccinees. To achieve this goal, optimal vaccine target, platform 151 and regimen are of high importance.¹⁷ Nowadays, more than 80 vaccines documented 152 in WHO are based on protein subunit platform, suggesting a major platform for COVID-153 154 19 vaccine development (http://www.who.int).

155 To response the pandemic, we launched a vaccine development program against

SARS-CoV-2. The resulting vaccine candidate, ZF2001, is one of the two protein 156 subunit vaccines that has advanced into phase 3 trial (NCT04646590). Compared with 157 158 other vaccine candidates in clinical trials targeting mainly whole virus or full-length spike (S) protein, ZF2001 targets SARS-CoV-2 S protein receptor-binding domain 159 (RBD). RBD is responsible for the engagement of its cellular receptor human 160 angiotensin converting enzyme 2 (hACE2) and is an attractive vaccine target to induce 161 immune responses focusing on blocking the receptor binding.²²⁻²⁴ We rationally 162 designed a dimeric form of SARS-CoV-2 RBD with high yields at level of g/L and 163 164 dramatically enhanced immunogenicity compared with the conventional monomeric form of RBD in animal model.²⁵ ZF2001 is formulated by RBD-dimer protein produced 165 in Chinese hamster ovary (CHO) cells adjuvanted with aluminum hydroxide. 166

We started the phase 1 trial from June 22, 2020 and phase 2 trial from July 12, 2020 in China for the vaccine candidate ZF2001. Here, we report the pooled analysis of both trials, in which, vaccine safety and immunogenicity were assessed. Appropriate vaccine dose and vaccination schedule were determined for efficacy evaluation in phase 3 trial.

172

173 **Methods:**

174

175 Trial design and participants

The phase 1 trial was conducted at two hospitals in China: The Second Affiliated
 Hospital of Chongqing Medical University (Chongqing) and Beijing Chao-Yang

Hospital of Capital Medical University (Beijing). The phase 2 trial was conducted at 178 Hunan provincial center for disease control and prevention (Xiangtan, China). Eligible 179 180 participants were healthy men and nonpregnant women, 18 to 59 years of age. Healthy status, assessed during the screening period, was based on medical history and 181 clinical laboratory findings, vital signs, and physical examination. Volunteers who had 182 a history of SARS or COVID-19, or were tested positive for SARS-CoV-2 exposure (by 183 real-time PCR assay or enzyme-linked immunosorbent assay [ELISA]), or contacted 184 with confirmed COVID-19 patients were excluded. Exclusion criteria also included a 185 186 history of seizures or mental illness; allergy to any ingredient in the vaccine; acute febrile disease in 24 hours and digestive diseases in 7 days before enrollment; 187 congenital or acquired immune diseases; serious chronic disease; abnormal chest CT 188 189 image; positive test of HBV, HCV, HIV and syphilis; tumor patients; receipt of any blood products in the past 3 months; receipt of any research medicines or vaccine in the past 190 3 month; and being unable to comply with the study schedule. Full details of the 191 192 eligibility criteria are described in the trial protocol provided in the appendix.

The trial was designed with double-blind, randomized and placebo-parallelcontrolled. Participants in phase 1 were divided into 3 groups at a ratio of 2:2:1 and allocated to receive three doses of vaccine (25 µg or 50 µg antigen dose) or placebo on day 0, 30 and 60. Participants in phase 2 were divided into six groups at a 1:1:1:1:1:1 ratio, with the former three groups receiving two doses of vaccine (25 µg or 50 µg antigen dose) or placebo, 30 days apart, while the latter three groups receiving three doses of vaccine (25 µg or 50 µg antigen dose) or placebo, 30 days apart.

Participants were recruited through community recruitment advertisements. All 200 participants provided written informed consent before enrollment in the trial. The trial 201 202 protocol was approved by the institutional review board of The Second Affiliated Hospital of Chongqing Medical University, Beijing Chao-Yang Hospital of Capital 203 Medical University, Hunan Provincial Center for Disease Control, Prevention and 204 National Medical Products Administration (NMPA), China and was performed in 205 accordance with the Declaration of Helsinki and Good Clinical Practice. Safety 206 oversight for specific vaccination pause rules and for advancement was performed by 207 208 an independent safety monitoring committee.

209

210 Randomisation and masking

211 The randomisation statisticians used SAS statistical software (version 9.4) to 212 generate the random table of participants in each dose group. These randomisation statisticians were not allowed to participate in other related work of these clinical trials 213 214 and not allowed to disclose the blind code to any personnel participating in this clinical 215 trial. The participants were randomly assigned to the experimental vaccine group or the placebo group according to the block randomisation method, with the block and 216 block size of 5 and 5, respectively, in phase 1 trial, and of 75 and 12, respectively, in 217 218 phase 2 trial. Investigators at trial site assign study numbers strictly according to the order of screening sequence of eligible subjects, and experimental vaccines were 219 obtained and administered according to the numbers. The participants, field 220 investigators and laboratory team were always blinded to group allocation during the 221

222 trial.

223

224 Procedures

The vaccine was jointly developed by Institute of Microbiology, Chinese Academy of 225 Sciences and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd. ²⁵ The vaccine was 226 manufactured according to current Good Manufacturing Practice by Zhifei Longcom 227 Biopharmaceutical Co., Ltd. The recombined vaccine encodes the SARS-CoV-2 RBD 228 229 antigen (residues 319-537) in dimeric form and was manufactured as a liquid formulation containing 25 µg or 50 µg per 0.5 mL in a vial, with aluminum hydroxide as 230 the adjuvant. Vaccines were stored at 2 °C to 8 °C before use. Vaccine or placebo was 231 232 administrated intramuscularly in the arm of each participant.

233 For both trials, participants were observed in the observation room for 30-60 minutes after each dose of vaccination for emerging adverse events. During 0-7 days after each 234 235 vaccination, any adverse events were self-reported by participants daily on the diary 236 cards, but verified by investigators. The adverse events during 8-30 days after each 237 vaccination were reported by participants through contact cards. All serious adverse events within 1 year after the first dose of vaccination were reported. Solicited local 238 239 adverse reactions at injection site within 7 days post-vaccination included pain, swelling, induration, redness, rash and pruritus and solicited systemic adverse 240 241 reactions within 7 days post-vaccination included fever, cough, dyspnea, diarrhea, anorexia, nausea, vomiting, muscle pain (non-vaccination site), arthritis, joint pain, 242 243 headache, fatigue, acute allergic reaction, irritation or inhibition and mental disorder. 244 Laboratory safety tests including routine blood, and serum chemistry and routine urine

were to assess any toxic effects post-vaccination. Adverse events and abnormal
changes in laboratory tests were graded according to the latest scale issued by China
NMPA (Version 2019).

The sera were collected to evaluate the binding responses against RBD antigen and 248 neutralizing activity against live SARS-CoV-2. Peripheral blood mononuclear cells 249 (PBMC) were collected to assess the specific T cell responses. Blood samples were 250 251 taken from participants at the scheduled site visits before the vaccination, on day 14, 252 30, 37, 60, 67, 90 since first vaccination in phase 1, and on day 14, 30, 44, 60, 74, 90 253 in phase 2. We used ELISA kits (Wantai BioPharm, Beijing, China) to evaluated the 254 binding antibody responses against the RBD proteins according to the manufacturer's protocol. We also assessed the neutralizing activities against live SARS-CoV-2 by 255 256 microcytopathogenic effect assay (See Appendix supplementary Methods). PBMCs 257 from whole blood were isolated and stored in liquid nitrogen in advance, then thawed before testing. An enzyme-linked immunospot (ELISpot) assay was used to quantify 258 259 the specific T-cell responses as previously reported method (See Appendix 260 supplementary Methods). PBMCs were stimulated with overlapping peptide pools covering RBD protein for about 20-24 hours before detection, and the number of spot-261 262 forming cells per 1,000,000 cells were calculated. We measured the cytokine secretion of IFN-γ, IL-2, IL-4 and IL-5 with BD[™] ELISPOT. 263

A panel of convalescent serum samples with PCR-positive SARS-CoV-2 infection were obtained from symptomatic hospitalized patients, outpatients and those with asymptomatic infection detected by health-care worker surveillance. The neutralizing

activities of these serum samples against live SARS-CoV-2 were measured by
 microcytopathogenic effect assay.

269

270 Outcomes

For phase 1 trial, primary outcome was the safety of the COVID-19 vaccine. Secondary outcome was the immunogenicity. For phase 2 trial, primary outcomes were both safety and immunogenicity.

The outcomes for safety were occurrence of the adverse events between first injection to 30 days after final injection, including all adverse events, adverse events related to vaccination, adverse events at grade 3 and above, adverse events lead to participants exit. It also included all serious adverse events occurred between first injection to 1 year after final vaccination. All adverse events and serious adverse events related to vaccination were analyzed. Comparison between groups with different doses and dose regimens were analyzed.

The outcomes for immunogenicity were the seroconversion rate and magnitude of the RBD-binding antibody, SARS-CoV-2 neutralizing antibody and T-cell cytokine production. Groups with different doses and schedules were compared and analyzed. Serum samples from vaccine group and the convalescents were compared to assess and interpret the immunogenicity of the vaccine.

286

287 Statistical analysis

288 Based on clinical consideration and recommendation of pilot trial and technical

guideline issued by the NMPA in China, the sample sizes for two trials were practical, 289 290 and were not determined on a formal statistical power calculation. We firstly compiled 291 statistics of the number and ratio of participants with adverse reactions or serious adverse reactions post-vaccination and compared safety difference among the dose 292 groups using Fisher's exact probability method. The RBD-binding antibodies, 293 neutralizing titers against live virus were calculated with positive proportion, geometric 294 mean titres (GMTs). The cytokine production was calculated with GMTs. We used the 295 Clopper-Pearson method to calculate 95% confidence intervals (CIs), x² test/Fisher 296 297 exact probability method to compare the proportion differences among the dose groups and Student's t-test to analyze significance of GMTs between different time points. 298 299 Statistical analyses were using SAS (version 9.4) and GraphPad Prism (version 8.0.1). 300

301 Role of the funding source:

302

303 The funders of the study had no role in data collection, data analysis, data 304 interpretation, or writing of the Article. All authors had full access to all the data in the 305 study and had final responsibility for the decision to submit for publication.

306

307 **Results:**

308

In phase 1, a total of 107 volunteers were recruited and screened for eligibility between June 22 and July 3, 2020 in Chongqing and Beijing, China (figure 1). 57

individuals were excluded, leaving 50 eligible participants in the trial. They were 311 randomly divided into 3 groups to receive vaccine (25 µg [n=20] or 50 µg [n=20] RBD-312 313 dimer, with adjuvant) or placebo (adjuvant-only [n=10]). The mean age of all participants was 32.6 years (SD 9.41; range 20.9-57.9), with balanced age and sex 314 distribution among vaccination groups (table 1). 8 out of 10 participants in placebo 315 group, 15 out of 20 participants in the 25 µg group and 18 out of 20 participants in 50 316 µg group completed three-dose immunization and follow-up visits as schedule (figure 317 1, appendix 1). 318

319 In phase 2, a total of 1085 volunteers were recruited and screened for eligibility 320 between July 12 and July 17, 2020, in Xiangtan, China (figure 1). 185 volunteers were excluded, and 900 volunteers were enrolled to participant the trial. They were randomly 321 322 assigned to 6 groups (n=150) to receive vaccine (25 µg or 50 µg RBD-dimer, with 323 adjuvant) or placebo (adjuvant-only) with either a two-dose or a three-dose schedule, 30 days apart. The mean age of the participants was 43.5 years (SD 9.17; range 18.8-324 325 59.7) with balanced age and sex distribution among vaccination groups (table 1). All 326 450 participants with two-dose schedule completed full vaccination and the follow-up visits. For participants with three-dose schedule, 146 out of 150 participants in placebo 327 328 group, 148 out of 150 participants in the 25 µg group and 148 out of 150 participants 329 in the 50 µg group received full vaccination and completed the follow-up visits (figure 1, appendix 1). 330

For the overall adverse events within 30 days post-vaccination in phase 1 trial, 6
(60%) of 10 participants in the placebo group, 14 (70%) of 20 participants in the 25 μg

group and 18 (90%) of 20 participants in the 50 µg group reported at least one adverse 333 event (figure 2, appendix 2). No statistical significance between these three groups 334 335 (P=0.1786). Within 7 days post each vaccination, most of the local and systemic reactogenicity was absent or mild (grade 1 or 2 adverse events). The most common 336 337 solicited local adverse reactions in the placebo, the 25 µg and 50 µg groups were injection-site pain, reported by 20%, 20% and 55%; redness, reported by 10%, 20% 338 and 20%; and itch, reported by 0%, 20% and 35%. The most common solicited 339 systemic adverse reactions in placebo, the 25 µg and 50 µg groups were cough, 340 341 reported by 0%, 5% and 15%; fever, reported by 0%, 10% and 0%; and headache, reported by 0%, 5%, 5% (figure 2, appendix 2). Two grade 3 (or above) adverse events 342 (10%) were reported in the 50 µg group. One was vaccine-related (swelling and 343 344 redness) and the other one was serious adverse event (rhabdomyolysis), but was 345 vaccine-unrelated as assessed by the investigators (appendix 9). No vaccine-related serious adverse events or adverse events of special interest were reported. 346

347 In phase 2 trial, the overall adverse events were low within 30 days after vaccination. 348 For participants receiving two-dose vaccinations, 37 (25%) in placebo group, 43 (29%) in the 25 µg group and 50 (33%) in the 50 µg group reported at least one adverse 349 350 event. For participants receiving three-dose vaccinations, 47 (31%) in placebo group, 351 72 (48%) in the 25 µg group and 65 (43%) in the 50 µg group reported at least one adverse event (figure 2, appendix 3). Within 7 days after each vaccination, most of the 352 353 local and systemic reactogenicity was absent or mild (grade 1 or 2 adverse events). The most common solicited local adverse reactions in placebo, the 25 µg and 50 µg 354

groups were injection-site pain, reported by 4%, 3% and 5% in two-dose participants, 355 3%, 12% and 12% in three-dose participants; swelling, reported by 1%, 4% and 6% in 356 357 two-dose participants, 1%, 14% and 13% in three-dose participants; induration, reported by 1%, 3% and 5% in two-dose participants, 0%, 9% and 7% in three-dose 358 359 participants; redness, reported by 1%, 8% and 8% in two-dose participants, 1%, 16% and 14% in three-dose participants; and itch, reported by 0%, 6% and 9% in two-dose 360 361 participants, 0%, 19% and 17% in three-dose participants. The most common solicited systemic adverse reactions in the placebo, the 25 µg and 50 µg groups were fever, 362 363 reported by 4%, 5% and 7% in two-dose participants, 8%, 8% and 7% in three-dose participants; cough, reported by 1%, 2% and 2% in two-dose participants, 1%, 1% and 364 0% in three-dose participants; and headache, reported by reported by 1%, 2% and 1% 365 366 in two-dose participants, 0%, 2% and 0% in three-dose participants; and fatigue, reported by 0%, 3% and 2% in two-dose participants, 3%, 0% and 0% in three-dose 367 participants (figure 2, appendix 3). 18 participants were reported grade 3 (or above) 368 369 adverse events, with 12 of them (1.3%) were vaccine-related, including redness (5 370 cases), swelling (3 cases), injection-site pain (1 cases), induration (1 case), headache (1 case) and cough (1 case). Seven participants were reported serious adverse events, 371 but none of them were considered to related to the study vaccine as assessed by the 372 373 investigators (appendix 9). Besides, no adverse events of special interest were 374 reported.

Regarding to the immunogenicity, in phase 1 trial we detected the serologic RBDbinding IgG titers by ELISA assay to assess the antibody responses. The baseline

377 antibody titres of the participants are shown in the appendix 4. At day 30 after the first immunization, the seroconversion rates were 61% for the 25 µg group and 79% for the 378 379 50 µg group; and were increased to 100% for both groups at day 30 after the second and third immunizations (figure 3A; appendix 5). At day 30 after the first dose, the 380 GMTs of vaccine-induced RBD-binding IgG were 23.1 (95% CI, 11.2-47.9) and 40.8 381 (95% CI, 22.5-74.0) for the 25 µg and 50 µg group, respectively; and were increased 382 to 1077.0 (95% CI, 663.7-1747.5) and 825.5 (95% CI, 486.9-1399.4) at day 30 after 383 the second dose; and were further enhanced to 2719.5 (95% CI, 1584.0-4668.8) and 384 2776.8 (95% CI, 1875.5-4111.2) at day 30 after the third dose (figure 3B; appendix 5). 385 The GMTs were markedly increased after the second and third doses in both groups. 386 To analyze the neutralizing antibody titres against live SARS-CoV-2, we measured the 387 388 50% neutralizing titres for the serum samples of the participants. The baseline titres of neutralizing antibodies of the participants are given in the appendix 4. At day 30 after 389 the second dose, seroconversion rates reached 93.3% in the 25 μ g group and 94.4% 390 391 in the 50 µg group. At day 7 after the third immunization, the seroconversion rates were 392 100% in both groups (figure 3C; appendix 6). The SARS-CoV-2-neutralizing GMTs were 14.0 (95% CI, 8.0-24.6) and 11.4 (95% CI, 6.6-19.8) in the 25 µg and 50 µg group, 393 respectively, at day 7 after the second dose; and further enhanced to 94.5 (95% Cl, 394 395 49.3-181.3) and 117.8 (95% CI, 64.6-214.9) in the 25 µg and 50 µg group, respectively, 396 at day 7 after the third dose (figure 3D; appendix 6). The neutralizing titres dramatically 397 increased after the second and the third immunizations in both groups. Meanwhile, a panel of 89 COVID-19 human convalescent serum samples was tested for comparison. 398

The GMT of neutralizing antibodies for the COVID-19 convalescent serum panel was
51 (95% CI, 38.3-70.5). Encouragingly, the neutralizing GMTs for both the 25 µg and
50 µg groups were approximately two times of the magnitude than human
convalescent samples (figure 3D).

403 In phase 2 trial, the baseline antibody titres of the participants are shown in the appendix 4. At day 30 after the first immunization, the seroconversion rates were 59% 404 and 65% for the 25 µg and 50 µg group, respectively, in two-dose participants; 63% 405 and 62% for the 25 µg and 50 µg group, respectively, in three-dose participants. At day 406 407 30 after the second immunization, the seroconversion rates were increased to 95% 408 and 97% for the 25 µg and 50 µg group, respectively, in two-dose participants; 96% and 94% for the 25 µg and 50 µg, respectively, in three-dose participants. At day 14 409 410 after the third immunization, the seroconversion rates were further increased to 99% and 97% for the 25 µg and 50 µg group, respectively, in three-dose participants (figure 411 3E; appendix 7). In participants with two-dose schedule, RBD-binding IgG GMTs 412 significantly increased from 19.4 (95% CI, 16.0-23.6) (30 days after the 1st 413 immunization) to 419.5 (95% CI, 325.8-540.1) (30 days after the 2nd immunization) for 414 the 25 µg group; and from 22.6 (95% CI, 18.5-27.6) (30 days after the 1st immunization) 415 to 344.8 (95% CI, 271.0-438.7) (30 days after the 2nd immunization) for the the 50 µg 416 417 group (appendix 7). In participants with three-dose schedule, RBD-binding IgG GMTs significantly increased after each immunization, from 24.4 (95% CI, 19.6-30.2) (30 418 days after the 1st immunization), to 467.3 (95% CI, 366.8-595.3) (30 days after the 2nd 419 immunization), and to 1782.3 (95% CI, 1440.2-2205.7) (14 days after the 3rd 420

immunization), for the 25 µg group; and from 22.2 (95% CI, 18.1-27.4) (30 days after 421 1st immunization), to 302.5 (95% CI, 234.2-390.6) (30 days after 2nd immunization), to 422 1140.0 (95% CI, 882.2-1473.2) (14 days after the 3rd immunization), for the 50 µg group 423 (figure 3F; appendix 7). Regarding to the neutralizing antibody titres against live SARS-424 CoV-2, seroconversion rates and GMTs were analyzed. For the participants with two-425 dose schedule, 76% and 72% were seroconverted in the 25 µg and 50 µg group, 426 respectively, at 14 days after the 2nd immunization (appendix 8). For the participants 427 with three-dose schedule, 83% and 73% were seroconverted at 14 days after the 2nd 428 429 immunization in the 25 µg and 50 µg group, respectively; and further increased to 97% and 93%, respectively, at 14 days after the 3rd immunization (figure 3G, appendix 8). 430 The neutralizing GMT against live SARS-CoV-2 in participants with three-dose 431 schedule was boosted from 19.5 (95% CI, 15.2-25.0) (14 days after 2nd immunization) 432 to 102.5 (95% CI, 81.8-128.5) (14 days after 3rd immunization) in the 25 µg group; and 433 from 12.6 (95% CI, 10.0-16.0) (14 days after 2nd immunization) to 69.1 (95% CI, 53.0-434 90.0) (14 days after 3rd immunization) in the 50 µg group (figure 3H, appendix 8). After 435 436 three-dose vaccination, both the 25 µg and 50 µg groups showed neutralizing GMTs exceeding the level of a panel of convalescent sera (figure 3H). Again, there is no 437 enhancement of neutralizing GMT for the participants receiving high vaccine dose (50 438 439 μ g) compared with those receiving low vaccine dose (25 μ g).

To assess the T-cell responses, we performed ELISpot assay for the peripheral blood mononuclear cells (PBMCs) of participants in phase 1 trial against SARS-CoV-2 RBD protein. T_H1 and T_H2 cell responses were measured by detection of the T_H1 cytokines IFN- γ , IL-2 and the T_H2 cytokines IL-4, IL-5. As expected, placebo group did not show obvious increase for all tested T-cell cytokines. By contrast, either the 25 µg or 50 µg group elicited moderate levels of both T_H1 (IFN- γ and IL-2) and T_H2 (IL-4 and IL-5) cytokine production post vaccinations (figure 4). Therefore, ZF2001 induced balanced T_H1/T_H2 responses in humans.

448

449 **Discussion**:

450

S protein RBD is an attractive vaccine target against coronavirus.²⁶ To date, a 451 number of vaccine candidates based on RBD have been demonstrated efficient in 452 animal models against SARS-CoV, MERS-CoV or SARS-CoV-2.¹⁷ Several RBD-based 453 COVID-19 vaccines are being evaluated in clinical trials.¹⁷ Clinical data have been 454 published for an RBD-based COVID-19 vaccine candidate, developed by 455 BioNTech/Pfizer. This candidate, BNT162b1, is based on mRNA strategy and showed 456 good immunogenicity in humans.^{14,15} Here, we reported the first clinical study for the 457 458 RBD-based protein subunit vaccine against coronavirus in a population of 950 health adult participants. 459

We found vaccination with different doses (25 or 50 μg) and schedules (two- or threedoses) were well-tolerated. The incidents of adverse reactions between vaccine groups and placebo groups were similar in both phase 1 and 2 trials, without statistical significance. Most of the adverse reactions were mild, with the most common symptoms being injection-pain, redness and swelling. These adverse reactions were anticipated for alum-adjuvanted protein subunit vaccines and were transient and resolved within 3-4 days post-vaccination. Compared with other COVID-19 vaccine candidates, such as mRNA vaccines or adenovirus-vectored vaccines, the occurrences of fever and fatigue were lower.^{3-7,10,11,13} Compared with another protein subunit vaccine, NVX-CoV2373, using Matrix-M1 as adjuvant, the occurrences of injection-site pain, fatigue, headache and nausea were lower, as well.¹²

Humoral responses have been considered as immune correlates of protection 471 against SARS-CoV-2.27-31 So far, humoral responses for several COVID-19 vaccine 472 473 candidates in clinical trials have been reported. It should be noted that currently it is difficult to compare different vaccine candidates as there are no standardized 474 neutralization assays. We used microcytopathic effect assay to determine neutralizing 475 476 antibody titres for the serum samples from vaccinees, with a panel of COVID-19 convalescent sera tested as the control. The comparative immunogenicity showed 477 three-dose of ZF2001 elicited neutralizing GMT two times greater than the GMT tested 478 479 for the convalescent sera. Notably, two mRNA-based vaccines and two adenovirus-480 vectored vaccines have been announced 70-90% efficacy in preventing COVID-19 in phase 3 clinical trials, with their vaccine-induced humoral responses being reported 481 similar or higher than those from the convalescent samples.^{3-5,13,18} Although the 482 483 interpretation of the vaccine immunogenicity can be influenced by the illness severity of the convalescent selected for comparison, our study indicated encouragingly that 484 485 ZF2001 has the potential to elicit protective humoral responses against COVID-19. Three-dose vaccination was found dramatically enhanced the antibody responses 486

compared with two-dose vaccination, however, increasing the antigen dose from 25
µg to 50 µg did not show an improvement for the immunogenicity. Therefore, vaccine
of 25 µg antigen with three-dose schedule was determined for efficacy evaluation in
phase 3 trial.

Cellular immune responses also play protective roles in SARS-CoV-2 491 infections.^{32,33} Virus-specific T-cell responses were associated with milder disease in 492 COVID-19 patients.³⁴ Based on the levels of spot-forming cells per million cells, 493 cytokines representing both T_H1 and T_H2 responses were moderately elicited post 494 495 vaccination. The moderated but balanced production of T_H1 and T_H2 cell-associated cytokines may benefit for the T-cell-mediated protection rather than the potential risk 496 of vaccine-enhanced respiratory disease which is presumably caused by predominant 497 T_H2-biased responses .³⁵ 498

This trial report has several limitations. First, the participants in both trials were 499 young adults aged from 18-59, not including juvenile and elderly persons, whereas, 500 501 the elderly is more vulnerable to SARS-CoV-2. Moreover, the participants had limited ethnic diversity, mainly the ethnic Han. These limitations will be addressed by our 502 outreach study for cohort covering broader age range and ethnic backgrounds. Second, 503 the immunogenicity was tested at day 30 post full vaccination in phase 1 and day 14 504 505 post full vaccination in phase 2, which cannot be assessed for the duration of the immune response. Immune responses at later timepoints including those at least 6 506 507 months post vaccination will be obtained in the follow-up visits and investigation. Third, there was still no benchmark to evaluate protective immune responses against COVID-508

509	19. Therefore, although ZF2001 induced neutralizing GMTs higher than the
510	convalescent samples, it is yet hard to predict its protective efficacy. Since no
511	participant had SARS-CoV-2 exposure, we were unable to assess the protective
512	efficacy and vaccine-associated enhanced diseases at this moment. This limitation will
513	be addressed in the ongoing international multi-center phase 3 trials.

Contributors:

GFG, LD and JY initiated and designed the vaccine. SY, YL (Yan Liu) and JY contributed to the protocol and design of the trials. XY, HR and LL were the study site principal investigators in phase 1 trial. FL was the study site principal investigators in phase 2 trial. LG and JL were responsible for the organization and supervision of the phase 2 trial. ZZ participated in the implementation of trials. YL (Yan Li), ZH, JY, JW, PH, CL, SM, XZ, XF, CW, XD, ST, FW and LW were contributed to the laboratory testing and assay development. ZC was responsible for the collection of convalescent serum samples. EH and CW were responsible for vaccine manufacture. YL (Yi Luo) did the statistical analysis. SY, LD, JY and GFG participated in the data collection and analysis for manuscript. LD, YL (Yan Li) and GFG contributed to the writing of the manuscript.

Declaration of interests

530 SY, EH, CW, and ZZ are employees of Anhui Zhifei Longcom Biopharmaceutical Co.

531	Ltd. YL (Yan Liu) is an employee of Chongqing Medleader Bio-Pharm Co. Ltd. YL (Yi
532	Luo) is an employee of Beijing Keytech Statistical Technology Co. Ltd. LD, YL, JY and
533	GFG are listed as inventors on pending patent applications for RBD- dimer- based CoV
534	vaccines. The pending patents for RBD- dimers as protein subunit vaccines for SARS-
535	CoV-2 have been licensed to Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, China.
536	

537 **Data sharing:**

538

539 Individual participant data will be made available on request, directed to the 540 corresponding author (GFG). After approval of a proposal, data can be shared through 541 a secure online platform.

542

543 **Acknowledgments:**

544

This work is funded by National Program on Key Research Project of China 545 (2020YFC0842300), National Science and Technology Major Projects of Drug 546 Discovery (2018ZX09101001), Strategic Priority Research Program of the Chinese 547 Academy of Sciences (XDB29010202) and Anhui Zhifei Longcom Biopharmaceutical. 548 We thank Fengcai Zhu, Hudachuan Jiang and Pengfei Jin from Jiangsu Provincial 549 Center of Disease Control and Prevention (Jiangsu, China) for their valuable help for 550 the manuscript preparation. We thank Yuhai Bi for providing the virus and the staff of 551 Biosafety Level 3 Laboratory for their help in live virus experiments (Institute of 552

Microbiology, Chinese Academy of Science) We thank Zhifang Ying and Zhen Chen
for their technical support in neutralization experiments (National Institute for Food and
Drug Control)

556

557 **Figure legends**:

558

559 Figure 1: Study profile for the phase 1 and phase 2 trials

560 The reasons why 17 participants (9 in phase 1, and 8 in phase 2) were not included

- in the according-to-protocol cohort for vaccination and immunogenicity analysis are
- 562 listed in the appendix 1.

563

Figure 2: Solicited and unsolicited adverse events in phase 1 and 2 trials

Adverse events within 7 days post each vaccination and overall adverse events within 30 days post full vaccination are shown as percentage of participants in each group. Adverse reactions and events were graded according to the scale issued by National Medical Products Administration, China. The mild and moderate adverse events are colored in blue. The grade 3 or above (severe) adverse events are colored in orange.

571

572 Figure 3: Humoral immune responses in phase 1 and phase 2 trials

573 Shown are humoral responses in phase 1 trial (A-D) and phase 2 trial (E-H).

574 Seroconversion rates (A and E) and geometric mean titres (GMTs) (B and F) of RBD-

575	binding antibody at different time points after vaccination are shown. Seroconversion
576	rates (C and G) and GMTs (D and H) of neutralizing antibody at different time points
577	after vaccination are shown. Error bars show 95% confidence intervals (CIs). The
578	horizontal dashed line indicated the limit of detection. HCS = human convalescent
579	serum.
580	

582 **Reference:**

- 5841Qiang, W. et al. Description of the First Strain of 2019-nCoV, C-Tan-nCoV Wuhan Strain585— National Pathogen Resource Center, China, 2020. China CDC Weekly 2020; 2:81-58682.
- 5872Mahase, E. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to588start next week. *BMJ* 2020; **371**: m4714.
- 589 3 Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine 590 against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised 591 controlled trial. *Lancet* 2020; **396**: 467-478.
- 592 4 Logunov, D. Y. *et al.* Safety and immunogenicity of an rAd26 and rAd5 vector-based 593 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-594 randomised phase 1/2 studies from Russia. *Lancet* 2020; **396**: 887-897.
- 5955Ramasamy, M. N. *et al.* Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine596administered in a prime-boost regimen in young and old adults (COV002): a single-597blind, randomised, controlled, phase 2/3 trial. *Lancet*, 2020; **396:**1979-1993.
- 598 6 Zhu, F. C. *et al.* Immunogenicity and safety of a recombinant adenovirus type-5-599 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, 600 double-blind, placebo-controlled, phase 2 trial. *Lancet* 2020; **396**; 479-488.
- 7 Zhu, F. C. *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus
 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised,
 first-in-human trial. *Lancet* 2020; **395**; 1845-1854.
- 6048Xia, S. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine,605BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet606Infect Dis 2020; published on line Oct 17. doi:10.1016/S1473-3099(20)30831-8.
- Stang, Y. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial. *Lancet Infect Dis* 2020; published on line Nov 17.
 doi:10.1016/S1473-3099(20)30843-4.
- 61110Anderson, E. J. *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine612in Older Adults. N Engl J Med 2020; **383:** 2427-2438.
- Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 Preliminary Report. *N Engl J Med* 2020 383:1920-1931.
- 61512Keech, C. et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein616Nanoparticle Vaccine. N Engl J Med 2020; 383: 2320-2332.
- 61713Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine618Candidates. N Engl J Med 2020; **383:** 2439-2450.
- 619
 14
 Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults.

 620
 Nature 2020; 586: 589-593.
- 62115Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell622responses. *Nature* 2020; **586:** 594-599.
- 623 16 Xia, S. et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and

624 625		Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA
625	47	2020; 324: 951-960.
626 627	17	Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. <i>Nature Reviews</i> <i>Immunology</i> 2020: publish online Dec 8. doi:10.1038/s41577-020-00480-0.
628	18	Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N
629	10	Engl J Med 2020; publish online Dec 10. doi:10.1056/NEJMoa2034577.
630	19	Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222)
631		against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,
632		South Africa, and the UK. Lancet 2020; publish online Dec 8.doi:10.1016/S0140-
633		6736(20)32661-1.
634	20	Mahase, E. Covid-19: Moderna applies for US and EU approval as vaccine trial reports
635		94.1% efficacy. <i>BMJ</i> 2020; 371 , m4709
636	21	Moore, J. P. & Klasse, P. J. COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not
637		Warped Minds. <i>J Virol t</i> 2020; 94: e01083-20.
638	22	Premkumar, L. et al. The receptor binding domain of the viral spike protein is an
639		immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci
640		<i>Immunol</i> 2020; 5: eabc8413.
641	23	Wang, N., Shang, J., Jiang, S. & Du, L. Subunit Vaccines Against Emerging Pathogenic
642		Human Coronaviruses. Front Microbiol 2020; 11: 298.
643	24	Wang, Q. et al. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human
644		ACE2. Cell 2020; 181: 894-904.
645	25	Dai, L. et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS,
646		and SARS. <i>Cell</i> 2020; 182: 722-733
647	26	Lu, G., Wang, Q. & Gao, G. F. Bat-to-human: spike features determining 'host jump' of
648		coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015; 23: 468-
649		478.
650	27	Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science
651		2020; 369: 806-811.
652	28	Addetia, A. et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2
653		in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol
654		2020; 58: e02107-20
655	29	Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus
656		macaques. <i>Nature</i> 2020; 586: 583-588.
657	30	Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2.
658		<i>Science</i> 2020; 369: 77-81.
659	31	Wang, H. et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with
660		Potent Protection against SARS-CoV-2. Cell 2020; 182: 713-721.
661	32	Sun, J. et al. Generation of a Broadly Useful Model for COVID-19 Pathogenesis,
662		Vaccination, and Treatment. Cell 2020; 182: 734-743.
663	33	Liu, W. J. et al. T-cell immunity of SARS-CoV: Implications for vaccine development
664		against MERS-CoV. Antiviral Res 2017; 137: 82-92.
665	34	Sekine, T. et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic
666		or Mild COVID-19. <i>Cell</i> 2020; 183: 158-168.
667	35	Su, S., Du, L. & Jiang, S. Learning from the past: development of safe and effective

668	COVID-19	vaccines.	Nat	Rev	Microbiol,	2020;	publish	online	Oct	16.
669	doi:10.1038	8/s41579-02	0-0046	62-у.						
670										
671										
672										
673										
674										
675										
676										
677										
678										
679										
680										
681										
682										
683										
684										
685										
686										
687										
688										
689										
690										
691										
692										
693										
694										
695										
696										
697										
698										
699										
700										
701										
702										
703										
704										
705										
706										
707										
708										
709										
710										
711										

712 Table 1: Baseline demographic characteristics of participants in phase 1 and phase 2

713 trials

	Cohort in phase 1			Cohort in phase 2					
	Placebo,	25 µg,	50 µg,	Placebo,	25 µg,	50 µg,	Placebo,	25 µg, 3-	50 µg,
	3-dose	3-dose	3-dose	2-dose	2-dose	2-dose	3-dose	dose	3-dose
	(n=10)	(n=20)	(n=20)	(n=150)	(n=150)	(n=150)	(n=150)	(n=150)	(n=150)
Ages,									
(year)									
Mean	32.5	31.7	33.6	44.1	43.04	44.4	43.4	42.7	43.2
(SD)	(11.3)	(9.7)	(8.5)	(9.3)	(9.6)	(8.4)	(8.9)	(9.4)	(9.4)
Median	29.4	26.7	34.1	46.1	43.7	45.3	44.4	43.7	43.7
Min May	21.0,	22.9,	20.9,	20.7,	18.8,	19.9,	20.7,	20.0,	19.3,
iviin, iviax	57.9	54.7	49.4	59.4	58.4	59.1	58.0	59.7	59.6
Ethnic									
group									
Chinese		20	10	140	150	150	140	150	140
Han	9 (90%)	20	(0.0%)	(00%)	(100%)	100	(00%)	100	140
nationality		(100%)	(90%)	(99%)	(100%)	(100%)	(99%)	(100%)	(99%)
Othere	4 (400())	0	2	1 (10/)	0	0	1 (10/)	0	2(10/)
Others	1 (10%)	0	(10%)	1 (1%)	0	0	1 (1%)	0	∠(1%)
Sex									
Mala	E (E00()	14	11	69 (459()	65	57	74	74 (470/)	63
IVIAIE	ə (50%)	(70%)	(55%)	00 (40%)	(43%)	(38%)	(49%)	11 (4770)	(42%)
Fomolo	E (E0%)	5 (50%) 6 (30%)	9	92 (559/)	85	93	76	70 (529/)	87
remale	5 (50%)		(45%) 82 (55	o∠ (ວວ%)	(57%)	(62%)	(51%)	79 (53%)	(58%)

715 Data are mean (SD) or n (%)





Mild/Moderate Grade 3

730

729 Figure 2













